Impact of GERD on Daily Life (NIS) (Alegria)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 15, 2007
Last updated: January 25, 2012
Last verified: January 2012

The aim of this study is to gather epidemiological data in a population of GERD patients in primary care with a history of erosive esophagitis (less than or equal to 3 years).


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Epidemiological, Observational Study to Describe Symptom Control and Impact on Daily Life of GERD in Patients With Erosive Gastroesophageal Reflux Disease.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To gather epidemiological data in a population of GERD patients [ Time Frame: After collection of all questionnaires ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the added value of a new patient questionnaire (GERD Impact Scale) as a useful tool for the initial and long-term management of GERD patients: determination of the appropriate treatment and evaluation of the response to treatment. [ Time Frame: After collection of all questionnaires ] [ Designated as safety issue: No ]

Enrollment: 2001
Study Start Date: June 2006
Study Completion Date: March 2008

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Primary & Specialty care units


Inclusion Criteria:

  • Patients with erosive esophagitis (endoscopical findings according to the Los Angeles Classification; grade A-D) currently not treated with a proton pump inhibitor, for whom the general practitioner (GP) has decided to initiate or change the treatment for GERD
  Contacts and Locations
Please refer to this study by its identifier: NCT00545883

  Show 112 Study Locations
Sponsors and Collaborators
Principal Investigator: E. Louis, PR ULG
  More Information

No publications provided

Responsible Party: AstraZeneca Identifier: NCT00545883     History of Changes
Other Study ID Numbers: NIS-GBE-NEX-2006/1
Study First Received: October 15, 2007
Last Updated: January 25, 2012
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases processed this record on April 23, 2014